+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Canada Bladder Cancer Market 2020-2026

  • ID: 5148073
  • Report
  • August 2020
  • Region: Canada
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • MORE
Canada Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other), by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026.

Canada bladder cancer market is estimated to grow modestly at a CAGR of around 8.6% during the forecast period. Canada has a considerable market of bladder cancer treatment due to the increasing healthcare expenditure and significant prevalence of bladder cancer coupled with surging aging population base across the nation. It has been observed that aged people are more prone to develop bladder cancer. American Cancer Society (ASC) estimates that around 9 out of 10 people with bladder cancer are aged 55 or above. Therefore, the surging aging population base in the country is expected to fuel the bladder cancer market growth across the country. Furthermore, a significant prevalence of bladder cancer has been observed in the nation. According to Bladder Cancer Canada, bladder cancer is the fifth most common cancer in Canada, being the fourth most common among men and 12th most common among women. Moreover, an estimated 9,000 Canadians are diagnosed with bladder cancer each year, thereby representing a potential pool of the population that may demand bladder cancer drugs for treatment.

Canada bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.

The companies which are contributing to the growth of the Canada bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launches, mergers, and acquisitions, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the Canada bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • White papers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. Canada Bladder Cancer Market Research and Analysis by Cancer Type
2. Canada Bladder Cancer Market Research and Analysis by Diagnosis
3. Canada Bladder Cancer Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive research methodology of the Canada bladder cancer market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Canada bladder cancer market.
  • Insights about market determinants which are stimulating the Canada bladder cancer market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Canada Bladder Cancer Market by Cancer Type
5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma
5.1.2. Squamous Cell Bladder Cancer
5.1.3. Adenocarcinoma
5.1.4. Others (Sarcomas, Carcinoma in Situ)
5.2. Canada Bladder Cancer Market by Diagnosis
5.2.1. Cystoscopy
5.2.2. Biopsy
5.2.3. Urinalysis
5.2.4. Urine Cytology
5.2.5. Intravenous Pyelogram (IVP)
5.2.6. Others (Biomarkers)
5.3. Canada Bladder Cancer Market by Treatment
5.3.1. Surgery
5.3.2. Chemotherapy
5.3.3. Immunotherapy
5.3.4. Radiation Therapy
5.3.5. Others (Targeted Therapy)

6. Company Profiles
6.1. Astellas Pharma Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Bristol-Myers Squibb Co.
6.5. Eli Lilly and Co.
6.6. F. Hoffmann-La Roche Ltd.
6.7. GlaxoSmithKline Plc
6.8. Johnson & Johnson Services, Inc.
6.9. Merck & Co., Inc.
6.10. Pfizer Inc.
6.11. Spectrum Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
3 of 3
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll